Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation THKKF


Primary Symbol: V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Comment by dt_coreon May 30, 2022 10:09am
146 Views
Post# 34716704

RE:RE:RE:RE:RE:RE:Let's see if this works. Trying to post the results:

RE:RE:RE:RE:RE:RE:Let's see if this works. Trying to post the results:As long as the company achieves profitability I'm not overly worried about the balance sheet. Taking a deeper dive on the balance sheet: Like many peers THNK has a pre-paid services model, meaning customers pay before the services are rendered, and that constitutes the deferred revenue portion of liabilites. That line item will always exist and grow as the firm does. The fact that they have capitilized leases as opposed to operating ones is also not concerning nor out of the ordinay. Most of the acquisition consideration is in shares, not cash so from a financial health standpoint its not a concern. However having a low share price means paying for those considerations will be more dilutive to shareholders than what management expected at the time of the deals (this is my biggest gripe with the company but even at current share prices it'll be fine, but it will mean that the share price upside many expected during the IPO will take longer to achieve). 

Looking at some of the credit metrics the company's leverage ratio is about 4.2x Adj. EBITDA at the close of the year. It's not a small amount but it's certainly not off market for an acquisitive company. If you assume Think exits the year at a $90mm rev and $7mm EBITDA run-rate with 48% gross margins and 15% top-line growth (low end of their expectations) then that debt number sinks to 2.7x by end of 2023. On an EV/S basis Think is currently trading at 0.7x 2023 (vs. 2.0x to 3.0x comparable average) and EV/EBITDA of 6.3x for 2023 (about half of comparables). That EV/EBITDA is a bit missleading given the operating leverage in the business so one has to look at that EBITDA growth which given the business model should be significantly higher than revenue growth particularly as the company enters 2023 and beyond..
<< Previous
Bullboard Posts
Next >>